Lotiglipron


Oral nonpeptide small-molecule glucagon-like peptide-1 receptor agonist

A selective, potent, orally bioavailable small-molecule agonist of the human glucagon-like peptide-1 receptor developed by Pfizer using Sosei Heptares stabilized-receptor technology, advanced through Phase 2 for type 2 diabetes and obesity, and subsequently discontinued owing to hepatic transaminase elevations in a subset of treated participants.

Abstract

Lotiglipron (PF-07081532) is an orally administered, nonpeptide, small-molecule agonist of the human glucagon-like peptide-1 receptor (GLP-1R) developed by Pfizer in collaboration with Sosei Heptares. The compound was designed through structure-based drug design leveraging Sosei Heptares proprietary StaR (stabilized receptor) technology platform, which enables crystallographic resolution of G-protein-coupled receptor conformations that are otherwise too unstable for conventional structural characterization. Lotiglipron binds within the transmembrane domain of the GLP-1R, activating the Gs-coupled adenylyl cyclase signaling cascade and increasing intracellular cyclic adenosine monophosphate (cAMP) in a manner functionally analogous to the endogenous incretin peptide GLP-1(7-36)amide but with the pharmacokinetic advantages of oral bioavailability, once-daily dosing without fasting requirements, and a plasma elimination half-life of approximately 21 to 27 hours that supports sustained receptor engagement across the dosing interval.

However, the Phase 2 study was terminated early following identification of hepatic transaminase elevations (alanine aminotransferase and/or aspartate aminotransferase greater than 3 times the upper limit of normal) in 6.0 to 6.6 percent of lotiglipron-treated participants versus 1.6 percent on placebo, with some individuals reaching elevations greater than 8 times the upper limit of normal. No cases of liver failure, symptomatic hepatitis, or Hy’s law were reported. In June 2023, Pfizer announced discontinuation of the lotiglipron clinical program based on the transaminase signal, pharmacokinetic data from Phase 1 drug-drug-interaction studies suggesting impaired hepatic drug transport or metabolism in a subset of participants, and the inability to prospectively identify at-risk individuals.

Lotiglipron is structurally characterized as a benzimidazole-piperidinyl-benzodioxole derivative bearing a chloropyridinyl substituent and an oxetanylmethyl group (molecular formula C31H31ClN4O5, molecular weight 575.05 g/mol as free base; CAS 2401892-75-7). The compound is not approved in any jurisdiction and is not in active clinical development. Research-grade lotiglipron is available from multiple chemical suppliers and remains a tool compound for the investigation of small-molecule GLP-1R agonist pharmacology, biased signaling, and hepatic metabolism of the oral GLP-1R agonist class. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph